Disease burden of congenital cytomegalovirus infection at school entry age: study design, participation rate and birth prevalence

Korndewal, Marjolein J.; Vossen, Ann C.T.M.; Cremer, Jeroen; Binnendijk, Robert S. van; Kroes, Aloys C.M.; Sande, Marianne A. B. van der; Oudesluys‐Murphy, Anne Marie; Melker, Hester E. de

doi:10.1017/s0950268815002708

Cited by 25 publications

(38 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study that looked at RSV hospitalizations among commercially and Medicaid insured infants also found higher rates of hospitalizations and more severe cases among Medicaid-insured infants 16 . Data from this study and others suggest that not all infants with symptomatic congenital CMV disease are diagnosed or captured using administrative healthcare claims 17, 18 . We observed a prevalence of symptomatic congenital CMV disease that was between one-half and one-third of the expected 5.0–7.5 per 10,000 prevalence in the United States 2 .…”

Section: Discussionmentioning

confidence: 85%

“…We observed a prevalence of symptomatic congenital CMV disease that was between one-half and one-third of the expected 5.0–7.5 per 10,000 prevalence in the United States 2 . One study by Diener et al 19 found that the proportion of diagnosed symptomatic congenital CMV cases may be as high as 30%, though other studies have found this proportion to be much lower, with <10% of symptomatic cases diagnosed 17, 18, 20 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009–2015

Leung

Dollard

Grosse

et al. 2018

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose To assess clinical characteristics and trends in valganciclovir use among infants diagnosed with congenital cytomegalovirus (CMV) disease in the United States. Methods We analyzed 2009–2015 medical claims from Truven Health MarketScan® Commercial Claims and Encounters and Medicaid databases. We identified infants with a live birth code in the first claim who were enrolled for at least 45 days. Among infants diagnosed with congenital CMV disease, identified by an ICD-9-CM or ICD-10-CM code of congenital CMV infection or CMV disease within 45 days of birth, we assessed codes for CMV-associated clinical condition within the same period, and hearing loss and valganciclovir claims within the first 180 days. Findings In the commercial and Medicaid databases, we identified 257 (2.5/10,000) and 445 (3.3/10,000) infants diagnosed with congenital CMV disease, respectively, among whom 135 (53%) and 282 (63%) had ≥1 CMV-associated condition, 30 (12%) and 32 (7%) had hearing loss, and 41 (16%) and 78 (18%) had valganciclovir claims. Among infants with congenital CMV disease who had valganciclovir claims, 37 (90%) among commercially-insured infants and 68 (87%) among Medicaid-insured infants had ≥1 CMV-associated condition and/or hearing loss. From 2009 to 2015, the proportion with valganciclovir claims increased from 0% to 29% among commercially-insured infants and from 4% to 37% among Medicaid-insured infants (p<0.0001). Implications During 2009–2015, there was a strong upward trend in valganciclovir claims among insured infants who were diagnosed with congenital CMV disease, the majority of whom had CMV-associated conditions and/or hearing loss.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009–2015

Leung

Dollard

Grosse

et al. 2018

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Details of the CROCUS study's design have been published previously . In short, children with and without cCMV were retrospectively identified.…”

Section: Methodsmentioning

confidence: 99%

“…When this was positive, a second, different, internally controlled quantitative polymerase chain reaction performed in triplicate was used for confirmation in cCMV‐positive children. This was also done in the selected cCMV‐negative comparison group . cCMV‐positive was defined as a positive result in both the screening and confirmation test.…”

Section: Methodsmentioning

confidence: 99%

Long‐term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study

Korndewal

Oudesluys‐Murphy

Kroes

et al. 2017

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…The study design has been published elsewhere 11. Parents of 73 693 children, born between 1 January and 30 September 2008, living in the Netherlands were invited to participate in the study between October 2012 and January 2013.…”

Section: Methodsmentioning

confidence: 99%

Healthcare costs attributable to congenital cytomegalovirus infection

et al. 2018

View full text Add to dashboard Cite

ObjectiveCongenital cytomegalovirus infection (cCMV) can cause symptoms at birth as well as long-term impairment. This study estimates cCMV-related healthcare costs in the Netherlands in early childhood.Design, setting and patientsIn a nationwide retrospective cohort study, 156 children with cCMV were identified by testing 31 484 neonatal dried blood spots for cCMV. Use of healthcare resources in the first 6 years of life by children with cCMV and a matched cCMV-negative control group were analysed. Mean costs per child were calculated by multiplying healthcare resource use by its reference prices.ExposureChildren with cCMV were compared with cCMV-negative children.Main outcome measuresThe average total healthcare costs per child were based on the average costs for hospital admissions and consultations by healthcare providers.ResultsMean healthcare costs of children with cCMV (€6113, n=133) were higher than children without cCMV (€3570, n=274), although statistically not significant, with a mean difference of €2544 (95% CI €-451 to €5538). The costs of children with long-term impairment were two times higher in children with cCMV (€17 205) compared with children without cCMV (€8332).ConclusionsChildren with cCMV, especially those with long-term impairment and those symptomatic at birth, accrue higher healthcare costs than cCMV-negative children in the first 6 years of life, although this is not statistically significant. This economic impact is of importance in the evaluation of preventive measures against cCMV.Trial registration numberNTR3582.

show abstract

Disease burden of congenital cytomegalovirus infection at school entry age: study design, participation rate and birth prevalence

Cited by 25 publications

References 37 publications

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009–2015

Valganciclovir Use Among Commercially and Medicaid-insured Infants With Congenital CMV Infection in the United States, 2009–2015

Long‐term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study

Healthcare costs attributable to congenital cytomegalovirus infection

Contact Info

Product

Resources

About